



February 10, 2023

Top Glove Medical (Thailand) Co., Ltd.
% David Lim
Executive Director
TG Medical (USA) Inc
165 North Aspan Avenue
Azusa, California 91702

Re: K222129

Trade/Device Name: Nitrile Examination Powder Free Glove, Blue Tested For Use With 32
Chemotherapy Drugs and Fentanyl Permeation Resistance Claim, Nitrile
Examination Powder Free Glove, Black Tested For Use With 32 Chemotherapy
Drugs and Fentanyl Permeation Resistance Claim

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC, OPJ, QDO

Dated: July 4, 2022

Received: November 7, 2022

Dear David Lim:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Allan Guan -S

For Bifeng Qian, M.D., Ph.D.
Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K222129

Device Name

Nitrile Examination Powder Free Glove, Blue Tested for Use with 32 Chemotherapy Drugs and Fentanyl Permeation Resistance Claim

Indications for Use (Describe)

An examination glove is a disposable glove intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

No	Test Chemotherapy Drug	Concentration (mg/ml)	Minimum breakthrough Detection Time (min)
1	Blenoxane	15	>240
2	Busulfan	6	>240
3	Carboplatin	10	>240
4	Carmustine (BCNU)	3.3	16.7
5	Cisplatin	1	>240
6	Cyclophosphamide	20	>240
7	Cytarabine	100	>240
8	Dacarbazine	10	>240
9	Daunorubicin HCl	5	>240
10	Docetaxel	10	>240
11	Doxorubicin HCl	2.0	>240
12	Etoposide	20	>240
13	Ellence	2	>240
14	Fludarabine	25	>240
15	Fluorouracil	50	>240
16	Ganciclovir	10	>240
17	Gemcitabine	38	>240
18	Idarubicin HCl	1	>240
19	Ifosfamide	50	>240
20	Irinotecan	20	>240
21	Mechlorethamine HCl	1	>240
22	Melphalan	5	>240
23	Methotrexate	25	>240
24	Mitomycin C	0.5	>240
25	Mitoxantrone HCl	2	>240
26	Oxaliplatin	5	>240
27	Paclitaxel	6.0	>240
28	Rituximab	10	>240
29	Thiotepa	10.0	35.0
30	Trisenox	1	>240
31	Vincristine Sulfate	1	>240
32	Vinorelbine	10	>240

Test Drug	Concentration	Minimum breakthrough Detection Time (min)
Fentanyl Citrate	100 mcg/2ml	>240

Please note that Carmustine and Thiotepa have extremely low permeation times of 16.7 minutes and 35 minutes respectively.

WARNING:

Do not use Carmustine

CAUTION:

Testing showed an average breakthrough time of 35 minutes with Thiotepa.

Type of Use (*Select one or both, as applicable*)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Indications for Use

510(k) Number (if known)

K222129

Device Name

Nitrile Examination Powder Free Glove, Black Tested for Use with 32 Chemotherapy Drugs and Fentanyl Permeation Resistance Claim

Indications for Use (Describe)

An examination glove is a disposable glove intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with Chemotherapy Drugs as per ASTM D6978-05 Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

No	Test Chemotherapy Drug	Concentration (mg/ml)	Minimum breakthrough Detection Time (min)
1	Blenoxane	15	>240
2	Busulfan	6	>240
3	Carboplatin	10	>240
4	Carmustine (BCNU)	3.3	14.2
5	Cisplatin	1	>240
6	Cyclophosphamide	20	>240
7	Cytarabine	100	>240
8	Dacarbazine	10	>240
9	Daunorubicin HCl	5	>240
10	Docetaxel	10	>240
11	Doxorubicin HCl	2.0	>240
12	Etoposide	20.0	>240
13	Ellence	2	>240
14	Fludarabine	2	>240
15	Fluorouracil	50	>240
16	Ganciclovir	10	>240
17	Gemcitabine	38	>240
18	Idarubicin HCl	1	>240
19	Ifosfamide	50	>240
20	Irinotecan	20	>240
21	Mechlorethamine HCl	1	>240
22	Melphalan	5	>240
23	Methotrexate	25	>240
24	Mitomycin C	0.5	>240
25	Mitoxantrone HCl	2	>240
26	Oxaliplatin	5	>240
27	Paclitaxel	6.0	>240
28	Rituximab	10	>240
29	Thiotepa	10.0	24.1
30	Trisenox	1	>240
31	Vincristine Sulfate	1	>240
32	Vinorelbine	10	>240

Test Drug	Concentration	Minimum breakthrough Detection Time (min)
Fentanyl Citrate	100 mcg/2ml	>240

Please note that Carmustine and Thiotepa have extremely low permeation times of 14.2 minutes and 24.1 minutes respectively.

WARNING:

Do not use Carmustine and Thiotepa

CAUTION:

Testing showed an average breakthrough time of 24.1 minutes with Thiotepa.

Type of Use (*Select one or both, as applicable*)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."